Rich Pipeline of Hepatitis Treatment

Hepatitis is the 10th leading cause of death worldwide and became a serious global health problem. About 2 billion people are suffering from Hepatitis worldwide.

Beacon Pharmaceuticals Limited is one the icon in providing treatment for global hepatitis sufferers. After the success in cancer treatment, Beacon is now producing and supplying latest Hepatitis drugs. Beacon has introduced all the latest Hepatitis drugs. Recently the company has introduced global 1st generic of Daclatasvir, the research molecule of Bristol Myer Squibb.

Beacon has rich pipeline of drugs for Hepatitis treatment and already introduced 7 latest drugs. Beacon is providing all these products in 54 countries under the Hepatitis support program.


The products manufactured by Beacon for Hepatitis treatment are as follows-

Brand Name Generic Name Dosage Form Pack Size
Darvoni Sofosbuvir INN 400 mg + Daclatasvir INN 60 mg Tablet 1×6’s
Daclavir Daclatasvir INN        60 mg Tablet 1×10’s
Soforal Sofosbuvir INN 400 mg Tablet 1×8’s
Pegin Peg-interferon α2a Injection 1’s (PFS)
Becovir Tenofovir Disoproxil Fumarate Tablet 1×8’s
Caviral Entecavir 0.5 ng Tablet 1×10’s
Simeprivir Simeprevir INN 150 mg Capsule 1×6’s

Beacon Pharma always introduced latest drugs for the deadly diseases. As a continuation this, Beacon has introduced almost all the latest drugs for Hepatitis treatment.